Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.82
ZGNX's Cash to Debt is ranked higher than
73% of the 921 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. ZGNX: 1.82 )
ZGNX' s 10-Year Cash to Debt Range
Min: 0.73   Max: 2.93
Current: 1.82

0.73
2.93
Equity to Asset 0.27
ZGNX's Equity to Asset is ranked higher than
51% of the 842 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. ZGNX: 0.27 )
ZGNX' s 10-Year Equity to Asset Range
Min: 0.09   Max: 0.31
Current: 0.27

0.09
0.31
F-Score: 4
Z-Score: -1.32
M-Score: 2.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -49.44
ZGNX's Operating margin (%) is ranked higher than
53% of the 870 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.37 vs. ZGNX: -49.44 )
ZGNX' s 10-Year Operating margin (%) Range
Min: -299.29   Max: -49.44
Current: -49.44

-299.29
-49.44
Net-margin (%) 21.19
ZGNX's Net-margin (%) is ranked higher than
94% of the 870 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.90 vs. ZGNX: 21.19 )
ZGNX' s 10-Year Net-margin (%) Range
Min: -313.81   Max: 21.19
Current: 21.19

-313.81
21.19
ROE (%) 21.26
ZGNX's ROE (%) is ranked higher than
94% of the 894 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.44 vs. ZGNX: 21.26 )
ZGNX' s 10-Year ROE (%) Range
Min: -491.54   Max: 23.3
Current: 21.26

-491.54
23.3
ROA (%) 6.55
ZGNX's ROA (%) is ranked higher than
83% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.27 vs. ZGNX: 6.55 )
ZGNX' s 10-Year ROA (%) Range
Min: -89.81   Max: 5.45
Current: 6.55

-89.81
5.45
ROC (Joel Greenblatt) (%) -172.06
ZGNX's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.08 vs. ZGNX: -172.06 )
ZGNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -509.09   Max: -169.61
Current: -172.06

-509.09
-169.61
Revenue Growth (3Y)(%) -31.70
ZGNX's Revenue Growth (3Y)(%) is ranked higher than
50% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. ZGNX: -31.70 )
ZGNX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -31.7
Current: -31.7

» ZGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ZGNX Guru Trades in Q1 2014

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 734,478 sh (-41.99%)
» More
Q2 2014

ZGNX Guru Trades in Q2 2014

Chuck Royce 734,478 sh (unchged)
» More
Q3 2014

ZGNX Guru Trades in Q3 2014

Jim Simons 501,280 sh (New)
Chuck Royce 734,478 sh (unchged)
» More
Q4 2014

ZGNX Guru Trades in Q4 2014

Jim Simons 644,132 sh (+28.50%)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ZGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 58.50
ZGNX's P/E(ttm) is ranked higher than
71% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.40 vs. ZGNX: 58.50 )
ZGNX' s 10-Year P/E(ttm) Range
Min: 50   Max: 81.74
Current: 58.5

50
81.74
PE(NRI) 19.70
ZGNX's PE(NRI) is ranked higher than
92% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.00 vs. ZGNX: 19.70 )
ZGNX' s 10-Year PE(NRI) Range
Min: 16.43   Max: 26.86
Current: 19.7

16.43
26.86
P/B 3.90
ZGNX's P/B is ranked higher than
66% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.76 vs. ZGNX: 3.90 )
ZGNX' s 10-Year P/B Range
Min: 2.5   Max: 202
Current: 3.9

2.5
202
P/S 4.80
ZGNX's P/S is ranked higher than
56% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.26 vs. ZGNX: 4.80 )
ZGNX' s 10-Year P/S Range
Min: 0.33   Max: 15.16
Current: 4.8

0.33
15.16
EV-to-EBIT -9.61
ZGNX's EV-to-EBIT is ranked higher than
57% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.20 vs. ZGNX: -9.61 )
ZGNX' s 10-Year EV-to-EBIT Range
Min: -19.7   Max: 113.5
Current: -9.61

-19.7
113.5
Current Ratio 1.76
ZGNX's Current Ratio is ranked higher than
63% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. ZGNX: 1.76 )
ZGNX' s 10-Year Current Ratio Range
Min: 1.25   Max: 3.24
Current: 1.76

1.25
3.24
Quick Ratio 1.46
ZGNX's Quick Ratio is ranked higher than
67% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. ZGNX: 1.46 )
ZGNX' s 10-Year Quick Ratio Range
Min: 1.25   Max: 2.54
Current: 1.46

1.25
2.54
Days Inventory 169.46
ZGNX's Days Inventory is ranked higher than
67% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.81 vs. ZGNX: 169.46 )
ZGNX' s 10-Year Days Inventory Range
Min: 133.82   Max: 419.33
Current: 169.46

133.82
419.33
Days Sales Outstanding 79.94
ZGNX's Days Sales Outstanding is ranked higher than
73% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 78.61 vs. ZGNX: 79.94 )
ZGNX' s 10-Year Days Sales Outstanding Range
Min: 46.47   Max: 79.94
Current: 79.94

46.47
79.94

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.20
ZGNX's Price/Median PS Value is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. ZGNX: 1.20 )
ZGNX' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 2.69
Current: 1.2

0.12
2.69
Earnings Yield (Greenblatt) -10.90
ZGNX's Earnings Yield (Greenblatt) is ranked lower than
53% of the 918 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ZGNX: -10.90 )
ZGNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -11.2   Max: 2.4
Current: -10.9

-11.2
2.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:Z08.Germany,
Zogenix Inc was formed as a Delaware Corporation on May 11, 2006. The Company is a pharmaceutical company that develops and commercializes therapies that address specific needs for people living with pain-related conditions and central nervous system disorders who needs treatment alternatives to help them return to normal daily functioning. The Company's first commercial product, Sumavel DosePro Needle-free Delivery System, was launched in January 2010. Sumavel DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Sumavel DosePro is the first drug product approved by the U.S. Food and Drug Administration, or FDA that allows for the needle-free, subcutaneous delivery of medication. Sumavel DosePro may offer a faster-acting and more efficacious treatment alternative to oral and nasal triptans and simple, convenient administration when compared to traditional, needle-based sumatriptan injection. The Company's strategy is to commercialize and develop differentiated central nervous system and pain therapeutics that can address significant unmet medical needs and overcome limitations of existing products. The Company's main product candidate, Zohydro ER, is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. The Company completed Phase 3 development of Zohydro ER in 2011, and submitted an NDA for Zohydro ER to the FDA in May 2012. The FDA approved the NDA for Zohydro ER in October 2013 and the Company launched the product on March 3, 2014. The Company also develops Relday, a proprietary, long-acting injectable formulation of risperidone using Durect Corporation's SABER controlled-release formulation technology through a development and license agreement with Durect Corporation. The Company's competitors include: AstraZeneca plc, Endo Pharmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., and Pfizer, Inc. In the United States, pharmaceutical products are subject to extensive regulation by the FDA.
» More Articles for ZGNX

Headlines

Articles On GuruFocus.com
Analysts Weigh in on Zogenix in Light of Selling Zohydro Mar 12 2015 
comment on ZGNX Mar 23 2013 
Weekly CFO Buys Highlight: NGL, UNTK, ZGNX, VTSS, RVSB Dec 24 2012 
(ZGNX) CEO Roger Hawley buys 10,000 Shares Dec 07 2010 

More From Other Websites
Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study Mar 26 2015
Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study Mar 26 2015
Pernix to Acquire Zohydro® ER Franchise from Zogenix, Inc. Mar 24 2015
Broadfin Buffs Up on Zogenix, Inc. (ZGNX) and Derma Sciences Inc (DSCI) Mar 19 2015
5 Highly Unusual Stock Moves of the Past Week Mar 14 2015
How to Trade the Market's Most-Active Stocks Mar 12 2015
ZOGENIX, INC. Files SEC form 10-K, Annual Report Mar 11 2015
The Gamble That Did Not Pay Off Mar 11 2015
Pernix Up On Deal For Zogenix Hydrocodone Franchise Mar 11 2015
Stocks Mixed as Crude Supplies Climb More Than Forecast Mar 11 2015
Zogenix (ZGNX) Stock Declines Today Following Sale of Zohydro Mar 11 2015
Stock Futures Prepare to Bounce Back After Tuesday's Selloff Mar 11 2015
Zogenix reports 4Q loss Mar 10 2015
Zogenix reports 4Q loss Mar 10 2015
Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing... Mar 10 2015
Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results Mar 10 2015
Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing... Mar 10 2015
Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results Mar 10 2015
Zogenix, Inc. (ZGNX) in Focus: Stock Jumps 8.1% - Tale of the Tape Mar 09 2015
Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2014 Financial... Mar 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK